AQR Capital Management’s Lifecore Biomedical LFCR Stock Holding History

AQR Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$59K	Sell	15,870 -301	-2%	-$2.08K	﹤0.01%	3708
2025 Q4	$132K	Buy	16,171 +3,574	+28%	+$26.4K	﹤0.01%	3437
2025 Q3	$92.7K	Buy	12,597 +1,146	+10%	+$8.67K	﹤0.01%	3376
2025 Q2	$93K	Buy	+11,451	New	+$77.2K	﹤0.01%	3189
2022 Q3	–	Sell	-21,782	Closed	-$217K	–	2263
2022 Q2	$217K	Sell	21,782 -29,093	-57%	-$288K	﹤0.01%	1974
2022 Q1	$589K	Sell	50,875 -10,108	-17%	-$113K	﹤0.01%	1756
2021 Q4	$677K	Buy	60,983 +1,379	+2%	+$13.4K	﹤0.01%	1720
2021 Q3	$550K	Buy	59,604 +3,073	+5%	+$33.4K	﹤0.01%	1829
2021 Q2	$636K	Sell	56,531 -4,950	-8%	-$57.1K	﹤0.01%	1802
2021 Q1	$652K	Buy	+61,481	New	+$691K	﹤0.01%	1735
2020 Q4	–	Sell	-20,658	Closed	-$201K	–	2229
2020 Q3	$201K	Buy	+20,658	New	+$197K	﹤0.01%	2059

Other funds holding LFCR

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management's LFCR Position: Q1 2026 in Review

AQR Capital Management reduced its Lifecore Biomedical (LFCR) stake by 1.9% in Q1 2026, selling an estimated $2.08K and leaving 15,870 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #3708.

AQR Capital Management first reported a position in LFCR in Q3 2020 and has held it in 11 quarters since. The position peaked at $677K in Q4 2021. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

AQR Capital Management held 15,870 shares of Lifecore Biomedical worth $59K as of Q1 2026.
AQR Capital Management sold 301 Lifecore Biomedical shares in Q1 2026, an estimated $2.08K.
Lifecore Biomedical made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3708 holding.
AQR Capital Management first reported a position in Lifecore Biomedical in Q3 2020 and has held it in 11 quarters since.
AQR Capital Management's Lifecore Biomedical position peaked at $677K in Q4 2021.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.